Financial Performance - In 2024, the company achieved a record revenue of 4.532 billion CNY, a year-on-year increase of 19.34% [3] - The net profit attributable to the parent company was 138 million CNY, up 20.09% from the previous year [3] - In Q1 2025, revenue reached 1.267 billion CNY, reflecting a 14.71% increase year-on-year [3] - The net profit for Q1 2025 was 61.22 million CNY, marking a 28.15% growth compared to the same period last year [3] Strategic Initiatives - The significant growth is attributed to the "dual-driven, full-chain symbiosis" strategy, focusing on optimizing business structure and enhancing innovation [3] - The company is actively expanding in the elderly health sector, providing chronic disease training and services through pharmacies [4] - Development of the "Fuman Medical" series targeting common diseases in the elderly, alongside the "Guojin" series of traditional Chinese medicine products [4] Brand Development - The company has established a comprehensive self-owned brand system with over 700 agency products covering various medical categories [5] - The "Shenhua Weikang" product line has seen substantial sales growth, indicating strong market potential [5] - The company is expanding its online retail presence through platforms like Douyin, JD, Tmall, and Pinduoduo [5] Market Expansion - The company plans to deepen its market presence in Zhejiang and Fujian, focusing on both existing advantages and new growth opportunities [6] - The "1234 strategy" aims to enhance collaboration across four major business platforms, creating a cohesive pharmaceutical health ecosystem [7] Future Outlook - The company will continue to expand its store network through new openings, acquisitions, and franchises, solidifying its leading position in Anhui [8] - Emphasis on balanced development across core business segments while enhancing brand influence and market share [8] - Ongoing commitment to digital transformation and operational efficiency to support high-quality growth [8]

4 、 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 5 月 8 日前访问网址 https://eseb.cn/1nOs3jqe5m8 或使用微信扫描下方小程序码进行会前提问，公 司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行 回答。 安徽华人健康医药股份有限公司（以下简称"公司"）已分别于 2025 年 4 月 25 日、29 日在巨潮资讯网上披露了《2024 年年度报告》及《2024 年年度报 告摘要》、《2025 年第一季度报告》。为便于广大投资者更加全面深入地了解公 司经营业绩、发展战略等情况，公司定于 2025 年 5 月 8 日（星期四）15:00-16:00 1、会议召开时间：2025 年 5 月 8 日（星期四）15:00-16:00 2、会议召开方式：网络互动方式 3、会议召开地点：价值在线（www.ir-online.cn） 证券代码：301408 证券简称：华人健康 公告编号：2025-032 安徽华人健康医药股份有限公司 关于举办2024年度暨2025年第一季度业绩 说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥1,266,847,107, representing a 14.71% increase compared to ¥1,104,366,687 in the same period last year[5] - Net profit attributable to shareholders was ¥61,222,277, up 28.15% from ¥47,772,301 in the previous year[5] - Basic earnings per share rose to ¥0.1531, reflecting a 28.22% increase from ¥0.1194 in the previous year[5] - The net profit for the current period is CNY 65,083,948.27, an increase of 24% compared to CNY 52,500,362.09 in the previous period[22] - The operating profit for the current period is CNY 84,384,004.88, up from CNY 69,401,473.12, reflecting a growth of approximately 21.6%[22] - The total comprehensive income attributable to the parent company is CNY 61,222,277.52, compared to CNY 47,772,301.04 in the previous period, marking a 28% increase[23] Cash Flow and Assets - The net cash flow from operating activities increased by 130.62% to ¥363,317,692 from ¥157,539,855 year-on-year[5] - The company's cash and cash equivalents decreased to ¥788,141,526.89 from ¥999,693,750.44, a decline of 21.11%[18] - The total cash and cash equivalents at the end of the period is CNY 320,092,515.84, down from CNY 572,496,711.00 at the end of the previous period[24] - The company reported a foreign exchange impact of CNY -7,532.83 on cash and cash equivalents[24] Operating Costs and Expenses - Operating costs increased by 13.47% to ¥841,486,683.18, driven by sales growth[10] - Total operating costs amounted to ¥1,175,205,083.11, up 13.76% from ¥1,032,719,031.44 in the prior period[21] - The company reported a significant increase in research and development expenses to ¥6,522,397.24, up from ¥6,196,651.12, indicating a focus on innovation[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,951[12] - The largest shareholder, He Jiale, holds 50.12% of shares, totaling 200,493,326 shares, with 51,000,000 shares pledged[12] - The second-largest shareholder, He Jialun, holds 6.89% of shares, totaling 27,572,335 shares[12] - The total number of shares held by the top 10 shareholders accounts for a significant portion of the company's equity, with the top four shareholders holding over 66% combined[12] - The company has no preferred shareholders as per the report[14] Investments and Future Plans - The company reported a significant increase in trading financial assets, which rose by 2656.27% to ¥275,626,500 due to increased investments in financial products[10] - The company plans to continue expanding its retail store network to support revenue growth in the future[10] - The company plans to expand its market presence and invest in new technologies, although specific strategies were not detailed in the call[21] Liabilities and Assets Overview - Total assets at the end of the reporting period were ¥4,951,051,382.59, a 2.55% increase from ¥4,828,108,351.67 at the end of the previous year[5] - Total liabilities rose to ¥2,825,502,684.35, an increase of 2.09% from ¥2,767,673,601.70[20] Miscellaneous - The company received government subsidies totaling ¥1,205,938.16, which positively impacted its financial performance[6] - The company recorded a 43.62% increase in asset disposal gains, amounting to ¥915,251.57, primarily from the disposal of non-current assets[10] - There are no changes in the restricted shares for major shareholders during the reporting period[15] - The company did not conduct an audit for the first quarter report[25]

华人健康（301408）公告，2025年第一季度营业收入12.67亿元，同比增长14.71%。净利润6122.23万 元，同比增长28.15%。 ...

Core Insights - Anhui Huaren Health Pharmaceutical Co., Ltd. reported a record high revenue of 4.532 billion yuan for 2024, representing a year-on-year growth of 19.34% [2] - The net profit attributable to the parent company reached 138 million yuan, with a year-on-year increase of 20.09%, while the net profit excluding non-recurring items was 129 million yuan, up by 21.81% [2] Group 1 - The company is advancing its "dual-driven, all-chain symbiosis" 1234 development strategy, focusing on pharmaceutical terminals as the core strategic anchor [2] - The revenue ratio of retail business to other business segments remained stable at 7:3, forming a unique ecological model that drives counter-cyclical growth [2][3] Group 2 - In the pharmaceutical agency sector, the company has established a comprehensive network covering 200,000 stores nationwide, including over 3,000 cooperative chain pharmacies [3] - The company has developed a product matrix of over 700 products across eight major series, covering more than 80% of common products at pharmacy terminals [3] Group 3 - The retail segment strategy focuses on deepening its presence in Anhui, targeting East China, and expanding to surrounding areas, achieving full coverage in 15 prefecture-level cities in Anhui [3] - The company added 440 new stores through a combination of new openings and acquisitions, including 70 self-built stores and 370 acquired stores [3] Group 4 - The company aims to continue enhancing its "ecological closed loop + digital intelligence-driven" strategy, focusing on R&D innovation, deepening terminal network layout, and improving overall service capabilities [3]

安徽华人健康医药股份有限公司 审计报告 苏公 W[2025]A585 号 目 录 | 1、 | 审计报告 | ………………………………………………1 | | --- | --- | --- | | 2、 | 合并资产负债表 | ………………………………………6 | | 3、 | 母公司资产负表 | ………………………………………8 | | 4、 | 合并利润表 | ……………………………………………10 | | 5、 | 母公司利润表 | …………………………………………11 | | 6、 | 合并现金流量表 | ………………………………………12 | | 7、 | 母公司现金流量表 | ……………………………………13 | | 8、 | 合并所有者权益变动表 | ………………………………14 | | 9、 | 母公司所有者权益变动表 | ……………………………16 | | | 10、财务报表附注 | …………………………………………18 | | | 11、事务所营业执照复印件 | | | | 12、事务所执业证书复印件 | | 13、签字注册会计师资质证明复印件 公证天业会计师事务所（特殊普通合伙） Gon ...

专项审核报告 目 录 安徽华人健康医药股份有限公司 关于业绩承诺实现情况的 关于业绩承诺实现情况的专项审核报告 苏公W[2025]E1242号 安徽华人健康医药股份有限公司全体股东： 我们接受委托，对后附的安徽华人健康医药股份有限公司（以下简称华人健康） 《关于控股子公司安吉县百姓缘大药房连锁有限公司业绩承诺完成情况的说明》进 行了专项审核。 一、管理层的责任 5、签字注册会计师资质证明复印件 1、关于业绩承诺实现情况的专项审核报告 …………………1 2、关于 2024 年度收购标的业绩承诺实现情况的说明………3 3、事务所营业执照复印件 4、事务所执业证书复印件 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 中国．江苏．无锡 Wuxi．Jiangsu．China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 按照企业会计 ...

证券代码：301408 证券简称：华人健康 公告编号：2025-021 安徽华人健康医药股份有限公司 关于提请股东大会授权董事会办理以简易程序向特定对象发 行股票相关事宜的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"）于2025年4月23日召 开第五届董事会第七次会议，审议通过了《关于提请股东大会授权董事会办理以 简易程序向特定对象发行股票相关事宜的议案》，根据《中华人民共和国公司法 》《中华人民共和国证券法》《上市公司证券发行注册管理办法》《深圳证券交 易所上市公司证券发行与承销业务实施细则》《深圳证券交易所上市公司证券发 行上市审核规则》等法律法规、规范性文件相关规定及《公司章程》规定，公司 董事会提请股东大会授权董事会办理以简易程序向特定对象发行融资总额不超 过人民币3亿元且不超过最近一年末净资产20%的股票，授权期限自2024年年度股 东大会审议通过之日起至2025年年度股东大会召开之日止。 本次授权事宜尚需提请公司2024年年度股东大会审议，现将有关情况公告如 下： 一、授权具体内容 （一）确认 ...

核查意见 华泰联合证券有限责任公司 关于安徽华人健康医药股份有限公司 控股子公司安吉县百姓缘大药房连锁有限公司 业绩承诺完成情况的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"）首次公 开发行股票并在创业板上市持续督导阶段的保荐人，根据《证券发行上市保荐业 务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》及《深圳证券交易所上市公司自 律监管指引第 13 号——保荐业务》等有关规定，对华人健康控股子公司安吉县 百姓缘大药房连锁有限公司（以下简称"安吉百姓缘"或"标的公司"）业绩承 诺情况进行了核查，并出具核查意见如下： 一、交易基本情况 公司于 2024 年 6 月 24 日召开第五届董事会第三次会议，审议并通过了《关 于收购安吉县百姓缘大药房连锁有限公司 46.01%股权的议案》。2023 年 6 月，华 人健康与王宇、安吉百姓缘签署股权转让协议，王宇将其持有的安吉百姓缘 ...

安徽华人健康医药股份有限公司 关于业绩承诺实现情况的 专项审核报告 目 录 1、关于业绩承诺实现情况的专项审核报告 …………………1 2、关于 2024 年度重大资产重组业绩承诺实现情况的说 明…………………………………………………………………3 5、签字注册会计师资质证明复印件 3、事务所营业执照复印件 4、事务所执业证书复印件 我们接受委托，对后附的安徽华人健康医药股份有限公司（以下简称华人健康） 《关于2024年度重大资产重组业绩承诺实现情况的说明》进行了专项审核。 一、管理层的责任 按照企业会计准则及中国证券监督管理委员会《上市公司重大资产重组管理办 法》的规定，真实、准确地编制并披露《关于2024年度重大资产重组业绩承诺实现 情况的说明》，以使其不存在虚假记载、误导性陈述或重大遗漏是华人健康管理层 的责任。 二、注册会计师的责任 我们的责任是在实施审核工作的基础上对华人健康管理层编制的《关于2024年 度重大资产重组业绩承诺实现情况的说明》发表意见。我们按照《中国注册会计师 其他鉴证业务准则第 3101号-历史财务信息审计或审阅以外的鉴证业务》的规定执行 了审核工作。该准则要求我们计划和实施审核工作 ...